Advance in microsatellite alterations and microRNA in blood of lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

SHENCheng , ZHOUKun , LIShuangjiang ,  CHEGuowei

Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

CHEGuowei, Email: cheguowei_hx@aliyun.com

Keywords：

Micro RNA; microsatellite instability; microsatellite instability; lung cancer; blood

DOI：

10.7507/1007-4848.201605005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The early detection, diagnosis and treatment of lung cancer are the key points to reduce mortality and improve the prognosis. Detecting tumor markers in blood is a minimally-invasive, cost-effective, easy to administer and approachable test. A microsatellite consists of a tract of tenderly repeated DNA motifs that range in length from two to five nucleotides. Microsatellite alterations (MA) have been described as two types: loss of heterozygosity (LOH) and microsatellite instability (MSI). MicroRNA (miRNA) is a noncoding RNA and protein involved in regulating gene expression in the transcription level. In recent years, some miRNA markers and microsatellite alterations show significant tumor association, tissue specific and stability. Therefore, we write this review to discuss the microsatellite alterations and microRNA in blood of lung cancer.

Citation： SHENCheng, ZHOUKun, LIShuangjiang, CHEGuowei. Advance in microsatellite alterations and microRNA in blood of lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(2): 147-151. doi: 10.7507/1007-4848.201605005 Copy

1.	Inamura K, Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med, 2016, 5(3): pii: E36. doi: 10.3390/jcm5030036.
2.	马沙蕊, 宋刘梅, 李冬民. miRNA-497在肿瘤中的研究进展. 国外医学(医学地理分册), 2015, 36(1): 75-78.
3.	Xue X, Zhu YM, Woll PJ. Circulating DNA and lung cancer. Ann N Y Acad Sci, 2006, 1075: 154-164.
4.	Cazzoli R, Buttitta F, Di Nicola M, et al. MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol, 2013, 8(9): 1156-1162.
5.	Ulivi P, Zoli W. MiRNAs as non-invasive biomarkers for lung cancer diagnosis. Molecules, 2014, 19(6): 8220-8237.
6.	Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res, 2013, 73(15): 4801-4809.
7.	Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers, 2013, 18(8): 679-686.
8.	Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. CR Seances Soc Biol FilC R Seances Soc Biol Fil, 1948, 142(3-4): 241-243.
9.	Baumann JL, Li M, Poulsen A, et al. Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer. Cancer Epidemiol, 2012, 36(1): e33-e39.
10.	Wang J, Lu C, Liu XY, et al. Distinguishing second primary tumors from lung metastasis in patients with postoperative non-small cell lung cancer by microsatellite analysis. Zhonghua Jie He He Hu Xi Za Zhi, 2007, 30(2): 103-107.
11.	Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol, 2015, 36(1): 7-19.
12.	Imperatori A, Rotolo N, Dominioni L, et al. Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. BMC Cancer, 2015, 15: 567.
13.	Sidransky D. Nucleic acid-based methods for the detection of cancer. Science, 1997, 278(5340): 1054-1059.
14.	Maesta I, Leite FV, Michelin OC, et al. Primary pulmonary choriocarcinoma after human chorionic gonadotropin normalization following hydatidiform mole: a report of two cases. J Reprod Med, 2010, 55(7-8): 311-316.
15.	Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med, 1996, 2(9): 1033-1035.
16.	Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn, 2009, 11(3): 182-185.
17.	Carozzi FM, Bisanzi S, Falini P, et al. Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis. Lung Cancer, 2010, 68(2): 216-221.
18.	Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res, 2007, 33(6): 289-301.
19.	程建保，杨和平，阮志华，等. 肺癌患者血浆游离性DNA的研究. 重庆医学, 2003, 3: 265-267.
20.	Ocak S, Sos ML, Thomas RK, et al. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J, 2009, 34(2): 489-506.
21.	Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res, 1999, 5(10): 2689-2692.
22.	Nawroz-Danish H, Eisenberger CF, Yoo GH, et al. Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer, 2004, 111(1): 96-100.
23.	Coulet F, Blons H, Cabelguenne A, et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res, 2000, 60(3): 707-711.
24.	Li D, Wei Y, Wang D, et al. MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-kappaB/MMP-9/VEGF pathways. Biochem Biophys Res Commun, 2016, 472(3): 465-470.
25.	Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5): 843-854.
26.	Kozomara A, Griffiths-Jones S. MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res, 2014, 42(Database issue): D68-73.
27.	Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 2008, 105(30): 10513-10518.
28.	Gyoba J, Shan S, Roa W, et al. Diagnosing lung cancers through examination of micro-rna biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Sci, 2016, 17(4): 494.
29.	Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer, 2012, 130(6): 1378-1386.
30.	Zhang H, Chen X. Serum/plasma microRNAs as biomarkers for lung cancer. Zhongguo Fei Ai Za Zhi, 2012, 15(1): 52-55.
31.	Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 2009, 112(1): 55-59.
32.	Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 2008, 110(1): 13-21.
33.	Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 2008, 141(5): 672-675.
34.	Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
35.	Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 2011, 4(6): 575-586.
36.	Del Vescovo V, Grasso M, Barbareschi M, et al. MicroRNAs as lung cancer biomarkers. World J Clin Oncol, 2014, 5(4): 604-620.
37.	Petriella D, De Summa S, Lacalamita R, et al. miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. Tumour Biol, 2016, 37(4): 5503-5513.
38.	Wang RJ, Zheng YH, Wang P, et al. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol, 2015, 8(1): s765-771.
39.	Kang SM, Lee HJ. MicroRNAs in human lung cancer. Exp Biol Med (Maywood), 2014, 239(11): 1505-1513.
40.	Roth C, Stuckrath I, Pantel K, et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One, 2012, 7(6): e38248.
41.	Tang Y, Cui Y, Li Z, et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J Exp Clin Cancer Res, 2016, 35(1): 7.
42.	Shi SB, Wang M, Tian J, et al. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. Transl Res, 2016, 170: 1-7.
43.	Peng H, Wang J, Li J, et al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci, 2016, 151: 235-242.
44.	Kim G, An HJ, Lee MJ, et al. Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer, 2016, 91: 15-22.
45.	Zhou R, Zhou X, Yin Z, et al. Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer. Oncotarget, 2015, 6(42): 44609-44622.
46.	Zhao G, Liu L, Zhao T, et al. Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. Tumour Biol, 2015, 36(5): 3693-3701.
47.	Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One, 2012, 7(2): e32307.

1. Inamura K, Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med, 2016, 5(3): pii: E36. doi: 10.3390/jcm5030036.
2. 马沙蕊, 宋刘梅, 李冬民. miRNA-497在肿瘤中的研究进展. 国外医学(医学地理分册), 2015, 36(1): 75-78.
3. Xue X, Zhu YM, Woll PJ. Circulating DNA and lung cancer. Ann N Y Acad Sci, 2006, 1075: 154-164.
4. Cazzoli R, Buttitta F, Di Nicola M, et al. MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol, 2013, 8(9): 1156-1162.
5. Ulivi P, Zoli W. MiRNAs as non-invasive biomarkers for lung cancer diagnosis. Molecules, 2014, 19(6): 8220-8237.
6. Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res, 2013, 73(15): 4801-4809.
7. Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers, 2013, 18(8): 679-686.
8. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. CR Seances Soc Biol FilC R Seances Soc Biol Fil, 1948, 142(3-4): 241-243.
9. Baumann JL, Li M, Poulsen A, et al. Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer. Cancer Epidemiol, 2012, 36(1): e33-e39.
10. Wang J, Lu C, Liu XY, et al. Distinguishing second primary tumors from lung metastasis in patients with postoperative non-small cell lung cancer by microsatellite analysis. Zhonghua Jie He He Hu Xi Za Zhi, 2007, 30(2): 103-107.
11. Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol, 2015, 36(1): 7-19.
12. Imperatori A, Rotolo N, Dominioni L, et al. Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. BMC Cancer, 2015, 15: 567.
13. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science, 1997, 278(5340): 1054-1059.
14. Maesta I, Leite FV, Michelin OC, et al. Primary pulmonary choriocarcinoma after human chorionic gonadotropin normalization following hydatidiform mole: a report of two cases. J Reprod Med, 2010, 55(7-8): 311-316.
15. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med, 1996, 2(9): 1033-1035.
16. Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn, 2009, 11(3): 182-185.
17. Carozzi FM, Bisanzi S, Falini P, et al. Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis. Lung Cancer, 2010, 68(2): 216-221.
18. Castagnaro A, Marangio E, Verduri A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res, 2007, 33(6): 289-301.
19. 程建保，杨和平，阮志华，等. 肺癌患者血浆游离性DNA的研究. 重庆医学, 2003, 3: 265-267.
20. Ocak S, Sos ML, Thomas RK, et al. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J, 2009, 34(2): 489-506.
21. Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res, 1999, 5(10): 2689-2692.
22. Nawroz-Danish H, Eisenberger CF, Yoo GH, et al. Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer, 2004, 111(1): 96-100.
23. Coulet F, Blons H, Cabelguenne A, et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res, 2000, 60(3): 707-711.
24. Li D, Wei Y, Wang D, et al. MicroRNA-26b suppresses the metastasis of non-small cell lung cancer by targeting MIEN1 via NF-kappaB/MMP-9/VEGF pathways. Biochem Biophys Res Commun, 2016, 472(3): 465-470.
25. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5): 843-854.
26. Kozomara A, Griffiths-Jones S. MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res, 2014, 42(Database issue): D68-73.
27. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 2008, 105(30): 10513-10518.
28. Gyoba J, Shan S, Roa W, et al. Diagnosing lung cancers through examination of micro-rna biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Sci, 2016, 17(4): 494.
29. Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer, 2012, 130(6): 1378-1386.
30. Zhang H, Chen X. Serum/plasma microRNAs as biomarkers for lung cancer. Zhongguo Fei Ai Za Zhi, 2012, 15(1): 52-55.
31. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol, 2009, 112(1): 55-59.
32. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol, 2008, 110(1): 13-21.
33. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 2008, 141(5): 672-675.
34. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
35. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 2011, 4(6): 575-586.
36. Del Vescovo V, Grasso M, Barbareschi M, et al. MicroRNAs as lung cancer biomarkers. World J Clin Oncol, 2014, 5(4): 604-620.
37. Petriella D, De Summa S, Lacalamita R, et al. miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. Tumour Biol, 2016, 37(4): 5503-5513.
38. Wang RJ, Zheng YH, Wang P, et al. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol, 2015, 8(1): s765-771.
39. Kang SM, Lee HJ. MicroRNAs in human lung cancer. Exp Biol Med (Maywood), 2014, 239(11): 1505-1513.
40. Roth C, Stuckrath I, Pantel K, et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One, 2012, 7(6): e38248.
41. Tang Y, Cui Y, Li Z, et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J Exp Clin Cancer Res, 2016, 35(1): 7.
42. Shi SB, Wang M, Tian J, et al. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. Transl Res, 2016, 170: 1-7.
43. Peng H, Wang J, Li J, et al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci, 2016, 151: 235-242.
44. Kim G, An HJ, Lee MJ, et al. Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer, 2016, 91: 15-22.
45. Zhou R, Zhou X, Yin Z, et al. Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer. Oncotarget, 2015, 6(42): 44609-44622.
46. Zhao G, Liu L, Zhao T, et al. Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. Tumour Biol, 2015, 36(5): 3693-3701.
47. Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One, 2012, 7(2): e32307.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Advance in microsatellite alterations and microRNA in blood of lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content